Stock Financial Ratios, Dividends, Split History

CHCT / Community Healthcare Trust Incorporated financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price29.68
Volume126,700.00
Market Cap ($M)539.21
Enterprise Value ($M)648.31
Book Value ($M)279.61
Book Value / Share15.38
Price / Book1.93
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 7,714,654
Weighted Average Number Of Shares Outstanding Basic 4,726,925
Weighted Average Number Of Diluted Shares Outstanding 4,726,925
Common Stock Shares Outstanding 7,596,940
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.01
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets399.79
Liabilities120.18
Quick Ration/a
Current Ration/a
Income Statement (mra) ($M)
Real Estate Revenue Net8,632,000.00
Other Real Estate Revenue0.00
Net Income-1.46
Earnings Per Share Basic-0.31
Earnings Per Share Diluted-0.31
Cash Flow Statement (mra) ($M)
Cash From Operations2.97
Cash from Investing-140.64
Cash from Financing-140.64
Identifiers and Descriptors
CUSIP20369C106
Central Index Key (CIK)1631569

Split History

Stock splits are used by Community Healthcare Trust Incorporated to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Community Healthcare Trust's (CHCT) CEO Timothy Wallace on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Welcome to the Community Healthcare Trust 2018 First Quarter Earnings Release Conference Call. On the call today, the company will discuss its 2018 first quarter financial results. It will also discuss progress made in various aspects of its business. Following the remarks, the phone lines will be open for a question-and-answer session.

5 Notable Dividend Increases From the Past Week — Including Apple Inc.

2018-05-07 investorplace
The S&P 500 headed slightly lower last week as a solid employment report on Friday helped the market recoup earlier losses. High expectations heading into earnings season, plus lingering trade war concerns and uncertainty over the Fed’s plans to raise rates, all weighed on sentiment. However, a handful of businesses added some good news with dividend increases. (158-0)

March Madness: Is There A Doctor In The House?

2018-03-20 seekingalpha
For those who saw the real Julius Erving, or Dr. J., you know exactly what I am talking about. (22-0)

CUSIP: 20369C106